Pathological mechanism (s) having Inhibits as Pathological action

1 Abeta inhibits late LTP in animal models of Alzheimers
2 Abeta inhibits LTP both in soluble and fibrillar conformational states
3 Abeta inhibits LTP through TNFalpha
4 Abeta inhibits nicotinic ACh receptors at pre-synaptic glutamatergic terminals
5 Abeta oligomer inhibits p-21 activated kinase and stimulates ROCK signalling
6 Abeta peptides block LTP in rat CA1 in vivo
7 Abeta42/Abeta40 ratio correlates with impaired LTP in a mouse model of Alzheimers
8 AD combined treatment with cholinesterase inhibitor and alpha-adrenergic agonist.
9 AMPA receptor downscaling in AD
10 Beta-amyloid blocks high frequency stimulation induced LTP but not nicotine enhanced LTP
11 beta-Amyloid impairs LTP/LTD
12 beta-amyloid reduces IA
13 Inhibition of I_L impairs LTP in CA1 in vivo
14 Model block of I_A
15 Muscarinic receptor agonists and nicotine may prevent neurodegeneration in AD
16 Nicotine enhances depressive actions of Abeta on LTP in rat CA1 region in vivo
17 Picomolar concentrations of abeta monomers disrupt LTP
18 Regulation of back-propagating action potentials in hippocampal neurons.
19 Sub-nanomolar concentrations of oligomeric beta amyloid inhibits late LTP in rats and mice
20 Synaptic integration is disrupted in an AD mouse model